Isoxazoline fibrinogen receptor antagonists
    5.
    发明授权
    Isoxazoline fibrinogen receptor antagonists 有权
    异恶唑啉纤维蛋白原受体拮抗剂

    公开(公告)号:US06476226B2

    公开(公告)日:2002-11-05

    申请号:US09905321

    申请日:2001-07-13

    IPC分类号: C07D21500

    摘要: This invention relates to novel isoxazolines and isoxazoles of formula (I): or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

    摘要翻译: 本发明涉及新的式(I)的异恶唑和异恶唑:或其药学上可接受的盐或前药形式。 本发明涉及可用作血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的新型异恶唑类,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂 用于抑制血小板聚集,作为血栓溶解剂,和/或用于治疗血栓栓塞性疾病。

    Spirocycle integrin inhibitors
    6.
    发明授权
    Spirocycle integrin inhibitors 失效
    螺环整合素抑制剂

    公开(公告)号:US5760029A

    公开(公告)日:1998-06-02

    申请号:US816580

    申请日:1997-03-13

    摘要: This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-���8-(2-pyridinylaminomethyl)-!-1-oxa-2-azaspiro-�4,5!-dec-2-en-3-yl!carbonylamino! propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

    摘要翻译: 本发明涉及新的杂环,包括(S)-2-苯基磺酰基氨基-3 - [[[8-(2-吡啶基氨基甲基) - ] - 氧杂-2-氮杂螺[4,5] - 癸-2-烯 -3-基]羰基氨基]丙酸,其可用作αvβ3整联蛋白和相关细胞表面粘附蛋白受体的拮抗剂,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物的方法 单独或与其它治疗剂组合用于抑制细胞粘附,血管生成障碍,炎症,骨退化,癌症转移,糖尿病性视网膜病变,血栓形成,再狭窄,黄斑变性以及由细胞粘附和/ 或细胞迁移和/或血管发生。

    Tetrahydrocyclopenta[b]indole androgen receptor modulators
    10.
    发明授权
    Tetrahydrocyclopenta[b]indole androgen receptor modulators 有权
    四氢环戊二烯并[b]吲哚雄激素受体调节剂

    公开(公告)号:US08486943B2

    公开(公告)日:2013-07-16

    申请号:US12989959

    申请日:2009-05-14

    IPC分类号: A61K31/403 C07D209/60

    摘要: The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating or preventing physiological disorders, particularly reduced bone mass, osteoporosis, osteopenia, reduced muscle mass or strength, or erectile dysfunction comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明提供式(I)化合物或其药学上可接受的盐; 包含式(I)化合物与合适的载体,稀释剂或赋形剂组合的药物组合物; 以及用于治疗或预防生理障碍,特别是骨量减少,骨质疏松症,骨质减少,肌肉质量或强度降低或勃起功能障碍的方法,其包括施用式(I)化合物或其药学上可接受的盐。